Heritage Valley Medical Group, Inc.

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes6 trials
• Chronic kidney disease2 trials
• Obesity2 trials
• Alzheimer disease1 trial
• Type 1 diabetes1 trial

Phase

• Phase 38 trials

Status

• Completed6 trials
• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company5 trials
• Novo Nordisk A/S2 trials
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial

Running trials

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

Closed trials

• Completed

  A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06045221· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

  NCT05275400· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Terminated

  Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source